Life Science Reit Plc (GB:LABS)
LSE:LABS
Top Page
Life Science Reit Plc
(LSE:LABS)
Select Model
Select Model
Rating:48Neutral
Price Target:
38.00 p
▼(-2.81% Downside)
Action:ReiteratedDate:12/07/25
The overall stock score is primarily driven by significant financial instability and negative corporate events. The managed wind-down proposal and asset liquidation plan are major concerns, overshadowing any short-term technical strengths. The lack of profitability and negative valuation metrics further contribute to a low score.
Positive Factors
Strong Balance Sheet
A debt-free balance sheet provides financial stability and flexibility, allowing the company to invest in growth opportunities without the burden of interest payments.
Negative Factors
Declining Revenue
Declining revenue indicates challenges in maintaining market share and customer base, potentially impacting long-term financial health and growth prospects.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Balance Sheet
A debt-free balance sheet provides financial stability and flexibility, allowing the company to invest in growth opportunities without the burden of interest payments.
Read all positive factors
Life Science Reit Plc (LABS) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£141.40M
Dividend YieldN/A
Average Volume (3M)1.26M
Price to Earnings (P/E)―
Beta (1Y)0.52
Revenue Growth4.55%
EPS Growth23.43%
CountryUK
EmployeesN/A
SectorReal Estate
Sector Strength53
IndustryREIT - Industrial
Share Statistics
EPS (TTM)N/A
Shares Outstanding350,000,000
10 Day Avg. Volume565,873
30 Day Avg. Volume1,260,832
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)0.51
Price to Sales (P/S)6.55
P/FCF Ratio-20.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.02
Revenue Forecast (FY)£23.93M
Life Science Reit Plc Business Overview & Revenue Model
Company Description
Life Science Reit Plc is an investment company, which intends to carry on business as a REIT. Its objective is to provide Shareholders with an attractive level of total return. The company was founded on July 27, 2021 and is headquartered in Londo...
How the Company Makes Money
Life Science Reit Plc generates revenue primarily through leasing its properties to tenants in the life sciences sector. The company enters into long-term lease agreements with pharmaceutical companies, biotech firms, and research institutions, en...
Life Science Reit Plc Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
60
Neutral
Cash Flow
55
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 21.04M | 20.31M | 19.94M | 15.71M | 532.00K |
| Gross Profit | 5.62M | 11.45M | 10.44M | 7.15M | 77.00K |
| EBITDA | 9.16M | 9.78M | 8.72M | -65.04M | -302.00K |
| Net Income | -30.67M | -13.98M | -21.71M | -27.61M | 7.74M |
Balance Sheet | |||||
| Total Assets | 374.95M | 401.19M | 410.70M | 447.82M | 361.40M |
| Cash, Cash Equivalents and Short-Term Investments | 4.72M | 5.57M | 14.34M | 45.61M | 165.96M |
| Total Debt | 126.40M | 122.24M | 107.92M | 109.83M | 0.00 |
| Total Liabilities | 141.89M | 138.42M | 126.96M | 128.37M | 10.82M |
| Stockholders Equity | 233.06M | 262.77M | 283.75M | 319.45M | 350.58M |
Cash Flow | |||||
| Free Cash Flow | -1.72M | -6.36M | -16.42M | -8.73M | 3.54M |
| Operating Cash Flow | 8.68M | 12.92M | 7.62M | -1.09M | 3.54M |
| Investing Cash Flow | -11.17M | -16.35M | -11.64M | -186.38M | -181.52M |
| Financing Cash Flow | -3.30M | -5.34M | -27.24M | 67.11M | 343.94M |
Life Science Reit Plc Technical Analysis
Positive
39.10
Price Trends
41.10
Negative
39.62
Positive
39.55
Positive
Market Momentum
-0.19
Negative
52.91
Neutral
69.52
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:LABS, the sentiment is Positive. The current price of 39.1 is below the 20-day moving average (MA) of 39.44, below the 50-day MA of 41.10, and below the 200-day MA of 39.55, indicating a neutral trend. The MACD of -0.19 indicates Negative momentum. The RSI at 52.91 is Neutral, neither overbought nor oversold. The STOCH value of 69.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:LABS.
Life Science Reit Plc Peers Comparison
UnderperformOutperform
Sector (65)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | £9.53B | 17.68 | 3.51% | 4.25% | -4.77% | ― | |
65 Neutral | $2.17B | 12.19 | 3.79% | 4.94% | 3.15% | 1.96% | |
64 Neutral | £1.23B | 5.45 | 7.18% | 2.52% | 12.73% | ― | |
63 Neutral | £1.85B | 12.12 | 4.48% | 3.93% | 2.30% | ― | |
63 Neutral | £2.46B | 14.75 | 6.03% | 7.30% | 0.96% | ― | |
57 Neutral | £716.73M | -2.68 | -5.24% | 7.31% | -1.67% | -120.18% | |
48 Neutral | £141.40M | -1.34 | -12.37% | ― | 4.55% | 23.43% |
* Real Estate Sector Average
GB:LABS
Life Science Reit Plc
40.40
-2.00
-4.72%
GB:DLN
Derwent London plc REIT
1,644.00
-41.82
-2.48%
GB:GPE
Great Portland Estates plc R.E.I.T.
303.60
29.26
10.67%
GB:PHP
Primary Health Properties plc R.E.I.T
94.70
6.34
7.18%
GB:SGRO
Segro plc (REIT)
704.80
108.21
18.14%
GB:WKP
Workspace Group plc R.E.I.T.
372.80
4.90
1.33%
Life Science Reit Plc Corporate Events
Business Operations and StrategyFinancial Disclosures
Life Science REIT Hit by Portfolio Devaluation Amid Weaker Lab Demand
Negative
Jan 9, 2026
Life Science REIT reported that the value of its property portfolio fell 7.8% to £332.6 million as at 31 December 2025, while its unaudited EPRA net tangible assets declined 13% to £201.8 million, or 57.7 pence per share, reflecting weak...
Executive/Board Changes
Life Science REIT Appoints New Senior Independent Director
Neutral
Dec 3, 2025
Life Science REIT plc has appointed Robert Naylor as the Senior Independent Non-Executive Director, replacing Richard Howell, who will remain as a Non-Executive Director and Chair of the Audit Committee. Naylor brings 29 years of experience in cap...
Business Operations and StrategyShareholder Meetings
Life Science REIT Approves New Investment Policy and Initiates Wind-Down
Neutral
Nov 24, 2025
Life Science REIT plc announced the approval of a new investment objective and policy by its shareholders, which includes a managed wind-down of the company. The decision was made at a general meeting where the majority of shareholders voted in fa...
Business Operations and StrategyDelistings and Listing Changes
Life Science REIT Proposes Managed Wind-Down and Asset Liquidation
Negative
Nov 4, 2025
Life Science REIT plc has announced the publication of a circular detailing a proposal for a Managed Wind-Down of the company, which includes a new investment objective and policy. This proposal, pending shareholder approval, aims to liquidate the...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.